keyword
MENU ▼
Read by QxMD icon Read
search

Interferon-beta

keyword
https://www.readbyqxmd.com/read/28214639/congenital-glioblastoma-with-distinct-clinical-and-molecular-characteristics-case-reports-and-a-literature-review
#1
Masahiro Kameda, Yoshihiro Otani, Tomotsugu Ichikawa, Akira Shimada, Koichi Ichimura, Isao Date
BACKGROUND: The molecular diagnosis of brain tumors is important in classifying tumors and determining appropriate treatment. Congenital glioblastoma multiforme (GBM) is a rare tumor that occurs in infants, and the prognosis is poor. Approximately 60 patients diagnosed as congenital GBM have been reported. However, few reports have conducted molecular analyses of congenital GBM. CASE DESCRIPTION: We describe two congenital GBM patients treated in our hospital, and report results of immunohistochemistry, fluorescent in situ hybridization (FISH), direct sequencing, and methylation analyses...
February 15, 2017: World Neurosurgery
https://www.readbyqxmd.com/read/28211024/comparative-effectiveness-research-of-disease-modifying-therapies-for-the-management-of-multiple-sclerosis-analysis-of-a-large-health-insurance-claims-database
#2
Aaron Boster, Jacqueline Nicholas, Ning Wu, Wei-Shi Yeh, Monica Fay, Michael Edwards, Ming-Yi Huang, Andrew Lee
INTRODUCTION: Limited data are available on the real-world effectiveness of newer oral disease-modifying therapies (DMTs) in multiple sclerosis. The purpose of this study was to retrospectively compare the real-world effectiveness of dimethyl fumarate (DMF), fingolimod, teriflunomide, and injectable DMTs in routine clinical practice based on US claims data. METHODS: Patients newly-initiating DMF, interferon beta (IFNβ), glatiramer acetate (GA), teriflunomide, or fingolimod in 2013 were identified in the Truven MarketScan Commercial Claims Databases (N = 6372)...
February 16, 2017: Neurology and Therapy
https://www.readbyqxmd.com/read/28209331/treatment-effectiveness-of-alemtuzumab-compared-with-natalizumab-fingolimod-and-interferon-beta-in-relapsing-remitting-multiple-sclerosis-a-cohort-study
#3
Tomas Kalincik, J William L Brown, Neil Robertson, Mark Willis, Neil Scolding, Claire M Rice, Alastair Wilkins, Owen Pearson, Tjalf Ziemssen, Michael Hutchinson, Christopher McGuigan, Vilija Jokubaitis, Tim Spelman, Dana Horakova, Eva Havrdova, Maria Trojano, Guillermo Izquierdo, Alessandra Lugaresi, Alexandre Prat, Marc Girard, Pierre Duquette, Pierre Grammond, Raed Alroughani, Eugenio Pucci, Patrizia Sola, Raymond Hupperts, Jeannette Lechner-Scott, Murat Terzi, Vincent Van Pesch, Csilla Rozsa, François Grand'Maison, Cavit Boz, Franco Granella, Mark Slee, Daniele Spitaleri, Javier Olascoaga, Roberto Bergamaschi, Freek Verheul, Steve Vucic, Pamela McCombe, Suzanne Hodgkinson, Jose Luis Sanchez-Menoyo, Radek Ampapa, Magdolna Simo, Tunde Csepany, Cristina Ramo, Edgardo Cristiano, Michael Barnett, Helmut Butzkueven, Alasdair Coles
BACKGROUND: Alemtuzumab, an anti-CD52 antibody, is proven to be more efficacious than interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis, but its efficacy relative to more potent immunotherapies is unknown. We compared the effectiveness of alemtuzumab with natalizumab, fingolimod, and interferon beta in patients with relapsing-remitting multiple sclerosis treated for up to 5 years. METHODS: In this international cohort study, we used data from propensity-matched patients with relapsing-remitting multiple sclerosis from the MSBase and six other cohorts...
February 10, 2017: Lancet Neurology
https://www.readbyqxmd.com/read/28205143/development-of-a-gastric-absorptive-immediate-responsive-oral-protein-loaded-versatile-polymeric-delivery-system
#4
Pierre P D Kondiah, Yahya E Choonara, Lomas K Tomar, Charu Tyagi, Pradeep Kumar, Lisa C du Toit, Thashree Marimuthu, Girish Modi, Viness Pillay
A multifunctional platform to deliver three diverse proteins of insulin, interferon beta (INF-β) and erythropoietin (EPO), using a novel copolymeric microparticulate system of TMC-PEGDMA-MAA, was synthesised as an intelligent pH-responsive 2-fold gastric and intestinal absorptive system. Physiochemical and physicomechanical studies proved the degree of crystallinity that supported the controlled protein delivery of the microparticulate system. The copolymer was tableted before undertaking in vitro and in vivo analysis...
February 15, 2017: AAPS PharmSciTech
https://www.readbyqxmd.com/read/28194741/deciphering-the-biophysical-effects-of-oxidizing-sulfur-containing-amino-acids-in-interferon-beta-1a-using-ms-and-hdx-ms
#5
Damian J Houde, George M Bou-Assaf, Steven A Berkowitz
Introduction of a chemical change to one or more amino acids in a protein's polypeptide chain can result in various effects on its higher-order structure (HOS) and biophysical behavior (or properties). These effects range from no detectable change to significant structural or conformational alteration that can greatly affect the protein's biophysical properties and its resulting biological function. The ability to reliably detect the absence or presence of such changes is essential to understanding the structure-function relationship in a protein and in the successful commercial development of protein-based drugs (biopharmaceuticals)...
February 13, 2017: Journal of the American Society for Mass Spectrometry
https://www.readbyqxmd.com/read/28170401/clinical-practice-of-analysis-of-anti-drug-antibodies-against-interferon-beta-and-natalizumab-in-multiple-sclerosis-patients-in-europe-a-descriptive-study-of-test-results
#6
Jenny Link, Ryan Ramanujam, Michael Auer, Malin Ryner, Signe Hässler, Delphine Bachelet, Cyprien Mbogning, Clemens Warnke, Dorothea Buck, Poul Erik Hyldgaard Jensen, Claudia Sievers, Kathleen Ingenhoven, Nicolas Fissolo, Raija Lindberg, Verena Grummel, Naoimh Donnellan, Manuel Comabella, Xavier Montalban, Bernd Kieseier, Per Soelberg Sørensen, Hans-Peter Hartung, Tobias Derfuss, Andy Lawton, Dan Sikkema, Marc Pallardy, Bernhard Hemmer, Florian Deisenhammer, Philippe Broët, Pierre Dönnes, Julie Davidson, Anna Fogdell-Hahn
Antibodies against biopharmaceuticals (anti-drug antibodies, ADA) have been a well-integrated part of the clinical care of multiple sclerosis (MS) in several European countries. ADA data generated in Europe during the more than 10 years of ADA monitoring in MS patients treated with interferon beta (IFNβ) and natalizumab have been pooled and characterized through collaboration within a European consortium. The aim of this study was to report on the clinical practice of ADA testing in Europe, considering the number of ADA tests performed and type of ADA assays used, and to determine the frequency of ADA testing against the different drug preparations in different countries...
2017: PloS One
https://www.readbyqxmd.com/read/28132841/phosphorylation-dependent-feedback-inhibition-of-rig-i-by-dapk1-identified-by-kinome-wide-sirna-screening
#7
Joschka Willemsen, Oliver Wicht, Julia C Wolanski, Nina Baur, Sandra Bastian, Darya A Haas, Petr Matula, Bettina Knapp, Laurène Meyniel-Schicklin, Chen Wang, Ralf Bartenschlager, Volker Lohmann, Karl Rohr, Holger Erfle, Lars Kaderali, Joseph Marcotrigiano, Andreas Pichlmair, Marco Binder
Cell-autonomous induction of type I interferon must be stringently regulated. Rapid induction is key to control virus infection, whereas proper limitation of signaling is essential to prevent immunopathology and autoimmune disease. Using unbiased kinome-wide RNAi screening followed by thorough validation, we identified 22 factors that regulate RIG-I/IRF3 signaling activity. We describe a negative-feedback mechanism targeting RIG-I activity, which is mediated by death associated protein kinase 1 (DAPK1). RIG-I signaling triggers DAPK1 kinase activation, and active DAPK1 potently inhibits RIG-I stimulated IRF3 activity and interferon-beta production...
February 2, 2017: Molecular Cell
https://www.readbyqxmd.com/read/28107165/interleukin-33-plasma-levels-in-patients-with-relapsing-remitting-multiple-sclerosis
#8
Fereshteh Alsahebfosoul, Ilnaz Rahimmanesh, Mansour Shajarian, Masoud Etemadifar, Nahid Sedaghat, Zahra Hejazi, Shamsi Naderi
Cytokines are implicated in the immunopathogenesis of multiple sclerosis (MS). Interleukin (IL)-33, one of the recently discovered members of the IL-1 superfamily, is a dual functional cytokine involved in various autoimmune disorders. In a case-control study, venous blood was collected from healthy subjects categorized as control group (n=44) and MS patients (n=44). All recruited patients were clinically diagnosed with relapsing-remitting MS (RRMS), including patients without treatment (new identified cases, n=16) and those treated with interferon beta (IFN-β) (n=28)...
January 20, 2017: Biomolecular Concepts
https://www.readbyqxmd.com/read/28104258/the-impact-of-betaplus-program-on-patient-treatment-satisfaction-with-interferon-beta-1b-in-multiple-sclerosis-multicentric-cross-sectional-survey-in-the-western-balkan-countries
#9
Jelena Drulovic, Mirjana Cukic, Sanja Grgic, Evica Dincic, Ranko Raicevic, Congor Nadj, Gordana Toncev, Slobodan Vojinovic, Sarlota Mesaros, Darija Kisic Tepavcevic, Irena Dujmovic, Daliborka Tadic, Svetlana Miletic-Drakulic, Jelena Dackovic, Smiljana Kostic, Jevto Erakovic, Lorand Sakalas, Dejan Savic, Vesna Suknjaja, Vanja Martinovic, Gorica Maric, Tatjana Pekmezovic
BACKGROUND: Long-term treatment adherence to disease-modifying drugs (DMDs) may have significant impact on clinical outcomes in multiple sclerosis (MS). It has been recently emphasized that low treatment satisfaction (TS) may be an important factor for achieving high rates of treatment adherence. Interferon (IFN) beta-1b was the first DMD approved for the treatment of MS. The aims of our study were to assess TS in subjects with relapsing-remitting (RR) MS treated with IFN beta-1b in Serbia, Montenegro and the Republika Srpska, Bosnia and Herzegovina (B&H), and additionally, to evaluate the impact of patient support program on TS and adherence...
January 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/28104250/impact-of-daclizumab-versus-interferon-beta-1a-on-patient-reported-outcomes-in-relapsing-remitting-multiple-sclerosis
#10
Ying Liu, Timothy Vollmer, Eva Havrdova, Katherine Riester, Andrew Lee, Glenn Phillips, Ping Wang, Guido Sabatella
BACKGROUND: Patient-reported outcomes (PROs) provide information on treatment effects from the patient's perspective that complement outcomes on clinical measures. In DECIDE, daclizumab demonstrated superior efficacy in reducing relapses, 24-week confirmed disability progression, and brain lesions (assessed by magnetic resonance imaging [MRI]) versus intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis. OBJECTIVE: To examine the impact of daclizumab versus interferon beta-1a on PROs in DECIDE...
January 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/28103257/activation-of-the-jak-stat-signaling-pathway-after-in-vitro-stimulation-with-ifn%C3%A3-in-multiple-sclerosis-patients-according-to-the-therapeutic-response-to-ifn%C3%A3
#11
Isaac Hurtado-Guerrero, Maria Jesús Pinto-Medel, Patricia Urbaneja, Jose Luis Rodriguez-Bada, Antonio León, Miguel Guerrero, Óscar Fernández, Laura Leyva, Begoña Oliver-Martos
Interferon beta (IFNß) is a common treatment used for multiple sclerosis (MS) which acts through the activation of the JAK-STAT pathway. However, this therapy is not always effective and currently there are no reliable biomarkers to predict therapeutic response. We postulate that the heterogeneity in the response to IFNß therapy could be related to differential activation patterns of the JAK-STAT signaling pathway. Our aim was to evaluate the basal levels and the short term activation of this pathway after IFNß stimulation in untreated and IFNß treated patients, as well as according to therapeutic response...
2017: PloS One
https://www.readbyqxmd.com/read/28098415/intracranial-aav-ifn-%C3%AE-gene-therapy-eliminates-invasive-xenograft-glioblastoma-and-improves-survival-in-orthotopic-syngeneic-murine-model
#12
Dwijit GuhaSarkar, James Neiswender, Qin Su, Guangping Gao, Miguel Sena-Esteves
The highly invasive property of glioblastoma (GBM) cells and genetic heterogeneity are largely responsible for tumor recurrence after the current standard-of-care treatment and thus a direct cause of death. Previously, we have shown that intracranial interferon-beta (IFN-β) gene therapy by locally administered adeno-associated viral vectors (AAV) successfully treats noninvasive orthotopic glioblastoma models. Here, we extend these findings by testing this approach in invasive human GBM xenograft and syngeneic mouse models...
February 2017: Molecular Oncology
https://www.readbyqxmd.com/read/28090055/natalizumab-is-effective-for-the-treatment-of-relapsing-remitting-tumefactive-multiple-sclerosis
#13
Masataka Nakamura, Kumi Itani, Kousuke Miyake, Takenobu Kunieda, Satoshi Kaneko, Hirofumi Kusaka
We herein report the case of a 57-year-old woman presenting with a biopsy-proven tumefactive demyelinating lesion as her first clinical event. Subsequently, she displayed a relapsing-remitting course with recurrence of large demyelinating lesions exceeding 2 cm in diameter rather than the small ovoid lesions characteristic of multiple sclerosis. Administration of interferon beta did not suppress the disease activity. Finally, treatment with natalizumab, which is a humanized monoclonal antibody against the cell-adhesion molecule α4-integrin, was initiated, resulting in clinical and radiological stabilization...
2017: Internal Medicine
https://www.readbyqxmd.com/read/28081190/inflammatory-activity-on-natalizumab-predicts-short-term-but-not-long-term-disability-in-multiple-sclerosis
#14
Joel Raffel, Arie R Gafson, Samer Dahdaleh, Omar Malik, Brynmor Jones, Richard Nicholas
BACKGROUND: In people with multiple sclerosis treated with interferon-beta or glatiramer acetate, new MRI lesions and relapses during the first year of treatment predict a poor prognosis. OBJECTIVE: To study this association in those receiving natalizumab. METHODS: Data were collected on relapses, new MRI activity, and Modified Rio Score after initiation of natalizumab in an observational cohort of 161 patients with high baseline disability...
2017: PloS One
https://www.readbyqxmd.com/read/28080250/no-evidence-of-disease-activity-in-patients-receiving-daclizumab-versus-intramuscular-interferon-beta-1a-for-relapsing-remitting-multiple-sclerosis-in-the-decide-study
#15
Ludwig Kappos, Eva Havrdova, Gavin Giovannoni, Bhupendra O Khatri, Susan A Gauthier, Steven J Greenberg, Xiaojun You, Ping Wang, Giorgio Giannattasio
BACKGROUND: No evidence of disease activity (NEDA) is a composite endpoint being increasingly applied as an outcome measure in clinical trials as well as proposed for individual therapeutic decisions in multiple sclerosis (MS). OBJECTIVE: Assess the proportion of patients with relapsing-remitting MS achieving NEDA in the DECIDE study of daclizumab 150 mg subcutaneous versus intramuscular interferon beta-1a 30 µg for 96-144 weeks. METHODS: NEDA was defined as no relapses, no onset of 12-week confirmed disability progression (CDP), no new/newly enlarging T2 hyperintense lesions (NET2), and no gadolinium-enhancing (Gd(+)) lesions...
December 1, 2016: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/28063616/chitinase-3-like-1-is-associated-with-the-response-to-interferon-beta-treatment-in-multiple-sclerosis
#16
Clara Matute-Blanch, Jordi Río, Luisa M Villar, Luciana Midaglia, Sunny Malhotra, José C Álvarez-Cermeño, Angela Vidal-Jordana, Xavier Montalban, Manuel Comabella
Chitinase 3-like 1 (CHI3L1) plays a prognostic role in patients with multiple sclerosis (MS). Here, we investigated a potential association between CHI3L1 and the response to interferon-beta (IFNβ) and glatiramer acetate (GA). Serum CHI3L1 levels were measured by ELISA in 117 relapsing-remitting MS (RRMS) patients, 76 IFNβ-treated and 41 GA-treated patients. CHI3L1 levels were increased by GA (p=0.014) but unchanged by IFNβ (p=0.830). CHI3L1 was associated with IFNβ response and levels were higher in non-responder group (p=0...
December 18, 2016: Journal of Neuroimmunology
https://www.readbyqxmd.com/read/28042704/development-of-an-in-vitro-immunobiotic-evaluation-system-against-rotavirus-infection-in-bovine-intestinal-epitheliocytes
#17
H Kobayashi, P Kanmani, T Ishizuka, A Miyazaki, J Soma, L Albarracin, Y Suda, T Nochi, H Aso, N Iwabuchi, J-Z Xiao, T Saito, J Villena, H Kitazawa
The bovine intestinal epithelial cell line (BIE cells) expresses the Toll-like receptor (TLR)3 and is able to mount an antiviral immune response after the stimulation with poly(I:C). In the present study, we aimed to further characterise the antiviral defence mechanisms in BIE cells by evaluating the innate immune response triggered by rotavirus (RV) infection. In addition, we attempted to determine whether immunobiotic bifidobacteria are able to confer protection of BIE cells against RV infection by beneficially modulating the antiviral immune response...
January 2, 2017: Beneficial Microbes
https://www.readbyqxmd.com/read/28028623/cognitive-impairment-and-structural-brain-changes-in-patients-with-clinically-isolated-syndrome-at-high-risk-for-multiple-sclerosis
#18
Eva Hynčicová, Martin Vyhnálek, Adam Kalina, Lukáš Martinkovič, Tomáš Nikolai, Jiří Lisý, Jakub Hort, Eva Meluzínová, Jan Laczó
Patients with clinically isolated syndrome (CIS), unlike those with multiple sclerosis (MS), have a selective cognitive impairment which is not consistently related to structural brain changes. Our objective was to characterize a profile of cognitive impairment and its association with structural brain changes in patients with CIS who are at high risk of developing MS. Patients with CIS at high risk for MS on interferon-beta (n = 51) and age-, gender-, and education-matched controls (n = 44) underwent comprehensive neuropsychological testing and MRI brain scan with voxel-based morphometry...
December 27, 2016: Journal of Neurology
https://www.readbyqxmd.com/read/28002679/ocrelizumab-versus-interferon-beta-1a-in-relapsing-multiple-sclerosis
#19
RANDOMIZED CONTROLLED TRIAL
Stephen L Hauser, Amit Bar-Or, Giancarlo Comi, Gavin Giovannoni, Hans-Peter Hartung, Bernhard Hemmer, Fred Lublin, Xavier Montalban, Kottil W Rammohan, Krzysztof Selmaj, Anthony Traboulsee, Jerry S Wolinsky, Douglas L Arnold, Gaelle Klingelschmitt, Donna Masterman, Paulo Fontoura, Shibeshih Belachew, Peter Chin, Nicole Mairon, Hideki Garren, Ludwig Kappos
Background B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a humanized monoclonal antibody that selectively depletes CD20+ B cells. Methods In two identical phase 3 trials, we randomly assigned 821 and 835 patients with relapsing multiple sclerosis to receive intravenous ocrelizumab at a dose of 600 mg every 24 weeks or subcutaneous interferon beta-1a at a dose of 44 μg three times weekly for 96 weeks. The primary end point was the annualized relapse rate. Results The annualized relapse rate was lower with ocrelizumab than with interferon beta-1a in trial 1 (0...
19, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/27999525/antidepressant-drug-treatment-in-association-with-multiple-sclerosis-disease-modifying-therapy-using-explorys-in-the-ms-population
#20
Matthew M Mirsky, Ruth Ann Marrie, Alexander Rae-Grant
Background: The Explorys Enterprise Performance Management (EPM) database contains de-identified clinical data for 50 million patients. Multiple sclerosis (MS) disease-modifying therapies (DMTs), specifically interferon beta (IFNβ) treatments, may potentiate depression. Conflicting data have emerged, and a large-scale claims-based study by Patten et al. did not support such an association. This study compares the results of Patten et al. with those using the EPM database. Methods: "Power searches" were built to test the relationship between antidepressant drug use and DMT in the MS population...
November 2016: International Journal of MS Care
keyword
keyword
34053
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"